<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756726</url>
  </required_header>
  <id_info>
    <org_study_id>CFT7455-1101</org_study_id>
    <nct_id>NCT04756726</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma</brief_title>
  <official_title>A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C4 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C4 Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,&#xD;
      pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with&#xD;
      Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered&#xD;
      once a day (QD) as a single agent and in combination with dexamethasone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">December 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 7, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Safety and tolerability of CFT7455</measure>
    <time_frame>Days 1-28</time_frame>
    <description>Percent of subjects with adverse events (AEs) with CFT7455 as a single agent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Safety and tolerability of CFT7455 for CFT7455 in combination with dexamethasone</measure>
    <time_frame>Days 1-28</time_frame>
    <description>Percent of subjects with AEs with CFT7455 in combination with dexamethasone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for CFT7455</measure>
    <time_frame>Baseline through 3 months after the last dose of study treatment</time_frame>
    <description>Percent of subjects with dose-limiting toxicities (DLTs) with CFT7455 as a single agent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: MTD or recommended RP2D for CFT7455 in combination with dexamethasone</measure>
    <time_frame>Baseline through 3 months after the last dose of study treatment</time_frame>
    <description>Percent of subjects with DLTs with CFT7455 in combination with dexamethasone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Antitumor activity of CFT7455</measure>
    <time_frame>Baseline through 6 months after the last dose of study treatment, or until disease progression, whichever occurs first</time_frame>
    <description>Overall Response Rate (ORR) based on Best Overall Response (BOR), Duration of Response (DOR), Clinical Benefit Rate (CBR), and Progression Free Survival (PFS) of CFT7455</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Antitumor activity of CFT7455 in combination with dexamethasone</measure>
    <time_frame>Baseline through 6 months after the last dose of study treatment, or until disease progression, whichever occurs first</time_frame>
    <description>ORR based on BOR, DOR, CBR, and PFS of CFT7455 as a single agent and in combination with dexamethasone in subjects with MM based on International Myeloma Working Group (IMWG) criteria</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma, Non-Hodgkin's</condition>
  <arm_group>
    <arm_group_label>Phase 1: Arm A - CFT7455</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r NHL or r/r MM will be treated with oral CFT7455 QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Arm B1 - CFT7455</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r MM will be treated with oral CFT7455 QD until the determination of maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Arm B2 - CFT7455 in combination with dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r MM will be treated with oral CFT7455 in combination with a fixed dose of oral dexamethasone in each cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Arm C - CFT7455</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r NHL will be treated with oral CFT7455 QD in each cohort until determination of MTD/RP2D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Arm 1 - CFT7455</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r MM will be treated with oral CFT7455</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Arm 2 - CFT7455 in combination with dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r MM treated with oral CFT7455 in combination with oral dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Arm 3 - CFT7455</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r mantle cell lymphoma (MCL) treated with oral CFT7455</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Arm 4 - CFT7455</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r peripheral T-cell lymphoma (PTCL) treated with oral CFT7455</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFT7455</intervention_name>
    <description>oral CFT7455 QD for 21 days of a 28-day cycle</description>
    <arm_group_label>Phase 1: Arm A - CFT7455</arm_group_label>
    <arm_group_label>Phase 1: Arm B1 - CFT7455</arm_group_label>
    <arm_group_label>Phase 1: Arm B2 - CFT7455 in combination with dexamethasone</arm_group_label>
    <arm_group_label>Phase 1: Arm C - CFT7455</arm_group_label>
    <arm_group_label>Phase 2: Arm 1 - CFT7455</arm_group_label>
    <arm_group_label>Phase 2: Arm 2 - CFT7455 in combination with dexamethasone</arm_group_label>
    <arm_group_label>Phase 2: Arm 3 - CFT7455</arm_group_label>
    <arm_group_label>Phase 2: Arm 4 - CFT7455</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Oral</intervention_name>
    <description>oral dexamethasone [ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; &gt;75 Years old: 20 mg QW on days 1, 8, 15, and 22]</description>
    <arm_group_label>Phase 1: Arm B2 - CFT7455 in combination with dexamethasone</arm_group_label>
    <arm_group_label>Phase 2: Arm 2 - CFT7455 in combination with dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be willing and able to provide signed informed consent for the trial.&#xD;
&#xD;
          2. Age ≥18 years at the time of signed consent.&#xD;
&#xD;
          3. Have histologically or cytologically-confirmed NHL or MM that is r/r disease and must&#xD;
             not be candidates for regimens known to provide clinical benefit to be eligible for&#xD;
             the study.&#xD;
&#xD;
          4. MM subject must have a documented diagnosis of MM and measurable disease at&#xD;
             enrollment. Measurable disease is defined as:&#xD;
&#xD;
               -  M-protein ≥0.5g/dL by Serum Protein Electrophoresis (sPEP) or&#xD;
&#xD;
               -  ≥200mg/24-hour urine collection by Urine Protein Electrophoresis (uPEP) or&#xD;
&#xD;
               -  Serum Free Light Chain (FLC) levels &gt;100 mg/L involved light chain and an&#xD;
                  abnormal kappa/lambda (κ/λ) ratio in subjects without measurable serum or urine&#xD;
                  M-protein or&#xD;
&#xD;
               -  For subjects with immunoglobulin class A (IgA), myeloma whose disease can only be&#xD;
                  reliably measured by quantitative immunoglobulin measurement, a serum IgA level ≥&#xD;
                  0.50g/dL.&#xD;
&#xD;
          5. Prior treatments for MM subjects must have the following:&#xD;
&#xD;
               -  Received at least 3 prior anti-myeloma regimens including at least 2 consecutive&#xD;
                  cycles of lenalidomide, pomalidomide, a proteasome inhibitor a glucocorticoid and&#xD;
                  an anti-CD38 antibody (induction with or without a bone marrow transplant with or&#xD;
                  without maintenance therapy is considered one regimen).&#xD;
&#xD;
               -  Refractory disease defined as disease that is nonresponsive to therapy (failure&#xD;
                  to achieve minimal response or development of progressive disease) or disease&#xD;
                  progression within 60 days from the last dose of their last myeloma therapy.&#xD;
&#xD;
          6. NHL subjects must have documented diagnosis of NHL and measurable disease defined by&#xD;
             measurable disease (consistent with Lugano classification) defined as at least one&#xD;
             lesion that can be accurately measured in at least two dimensions with PET-CT,&#xD;
             documented within 4 weeks of their projected cycle one day one (C1D1) visit. Minimum&#xD;
             measurement must be &gt;15 mm in the longest diameter.&#xD;
&#xD;
          7. NHL subjects must have received the following regarding prior therapy:&#xD;
&#xD;
               -  Peripheral T-cell Lymphoma: At least one prior line containing alkylator-based&#xD;
                  chemotherapy. Note: For subjects with Anaplastic Large Cell Lymphoma (ALCL), the&#xD;
                  subject must also have received CD30 antibody therapy.&#xD;
&#xD;
               -  Mantle Cell Lymphoma: ≥2 lines of therapy, including CD20 antibody and alkylator&#xD;
                  chemotherapy, and a Bruton's tyrosine kinase (BTK) inhibitor.&#xD;
&#xD;
               -  Follicular Lymphoma: ≥2 lines of therapy, including CD20 antibody therapy and&#xD;
                  alkylator chemotherapy.&#xD;
&#xD;
               -  Diffuse Large B-cell Lymphoma: ≥2 lines of therapy, including prior CD20 antibody&#xD;
                  therapy, and has received prior autologous bone marrow transplant (or is&#xD;
                  ineligible for bone marrow transplant).&#xD;
&#xD;
               -  Other NHL: Subjects must have been treated with all standard of care therapies&#xD;
                  available to the subject which, in the assessment of the investigator, may be&#xD;
                  beneficial to the subject.&#xD;
&#xD;
          8. A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               -  A woman of non-childbearing potential (i.e., physiologically incapable of&#xD;
                  becoming pregnant) defined as pre-menopausal females with a documented tubal&#xD;
                  ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous&#xD;
                  amenorrhea [in questionable cases a blood sample with simultaneous follicle&#xD;
                  stimulating hormone (FSH) &gt; 40 MIU/mL and estradiol &lt; 40 pg/mL (&lt;147 pmol/L) must&#xD;
                  be obtained].&#xD;
&#xD;
               -  Females on hormone replacement therapy (HRT) and whose menopausal status is in&#xD;
                  doubt will be required to use one of the contraception methods specified in the&#xD;
                  study protocol if they wish to continue their HRT during the study. Otherwise,&#xD;
                  they must discontinue HRT to allow confirmation of postmenopausal status prior to&#xD;
                  study enrollment.&#xD;
&#xD;
               -  Agree to having ongoing pregnancy tests during the study and after&#xD;
                  discontinuation of the study.&#xD;
&#xD;
          9. A male participant must have either had a prior vasectomy or agree to use a condom&#xD;
             during the treatment period and for at least 90 days after the last dose of study&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of central nervous system (CNS) disease.&#xD;
&#xD;
          2. Has received prior radiotherapy within 2 weeks of start of study treatment.&#xD;
&#xD;
          3. Have active pneumonitis.&#xD;
&#xD;
          4. Have any of the following:&#xD;
&#xD;
               -  Non-secretory or oligosecretory MM&#xD;
&#xD;
               -  Plasma cell leukemia&#xD;
&#xD;
               -  Systemic light chain amyloidosis&#xD;
&#xD;
               -  Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin&#xD;
                  changes (POEMS) Syndrome&#xD;
&#xD;
               -  Lymphoblastic lymphoma&#xD;
&#xD;
               -  Mycosis fungoides&#xD;
&#xD;
               -  Sezary syndrome&#xD;
&#xD;
               -  Primary cutaneous T-cell lymphomas&#xD;
&#xD;
               -  Primary CNS lymphoma&#xD;
&#xD;
               -  B-cell or T-cell prolymphocytic leukemia&#xD;
&#xD;
          5. Subjects with a peripheral neuropathy ≥ Grade 2.&#xD;
&#xD;
          6. Known malignancy other than study indication that is progressing or has required&#xD;
             treatment within the past three years.&#xD;
&#xD;
          7. Received live, attenuated vaccine within four weeks of first dose.&#xD;
&#xD;
          8. Known history of human immunodeficiency virus (HIV) infection. No HIV testing is&#xD;
             required unless mandated by local health authority.&#xD;
&#xD;
          9. Subjects with positive test for Hepatitis B surface (HBS-Ag) or Hepatitis B core (HBc)&#xD;
             antigen.&#xD;
&#xD;
         10. Subjects with positive test for hepatitis C (HCV) infection are excluded regardless of&#xD;
             viral load. If hepatitis C antibody test is positive, a confirmatory test should be&#xD;
             performed. If the test is negative, subject is eligible for this trial.&#xD;
&#xD;
         11. Concurrent administration of strong CYP3A modulators.&#xD;
&#xD;
         12. Is pregnant, breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
         13. Subjects on proton pump inhibitors (PPIs). The last dose of PPIs must be administered&#xD;
             seven days prior to administration of study drug. Antacids are acceptable when&#xD;
             administered in a staggered dosing manner with CFT7455.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Mahler, MD</last_name>
    <role>Study Director</role>
    <affiliation>C4 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vice President of Clinical Development</last_name>
    <phone>(617) 231-0700</phone>
    <email>clinicaltrials@C4therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute (Sarah Cannon Research Institute)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mt Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology (Sarah Cannon Research Institute)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lymphoma, Non-Hodgkin's</keyword>
  <keyword>CFT7455</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

